马瓦卡门在阻塞性过敏性心肌病中 - - 澳大利亚的第一次经验
Antony Chun Fai So1, Kathryn A Davison2, Teresa Hecker3
1Department of Cardiovascular Medicine, Flinders Medical Centre, Bedford Park, SA, Australia; College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia; Cardiac Imaging Research, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
Heart, lung & circulation
|January 23, 2026
概括
马瓦卡门在澳大利亚患者中显著降低了阻塞性多变性心肌病 (oHCM) 症状和左心室外流通道 (LVOT) 梯度. 心脏髓酶抑制剂在24周内表现出可容忍的安全性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 马瓦卡门,一种新型心脏肌抑制剂,已在澳大利亚批准用于阻塞性多变性心肌病 (oHCM).
- 国际研究证实了Mavacamten的有效性,但实际的澳大利亚数据缺乏.
- 这项研究解决了对澳大利亚对mavacamten影响和安全的现实数据的需求.
研究的目的:
- 评估澳大利亚患有症状的oHCM患者中mavacamten的实际有效性.
- 在这个群体中评估mavacamten的安全性和耐受性.
- 在24周内分析血液动力学和功能性参数的变化.
主要方法:
- 一项单一中心的观察性研究,包括23名患有oHCM症状的患者,接受了mavacamten治疗.
- 评估基线和24周心声学参数 (LVOT梯度,LVEF,LV全球纵向功能) 和NYHA类.
- 监测治疗出现的不良事件和患者的坚持.
主要成果:
- 马瓦卡门显著降低休息 (56至16 mmHg) 和瓦萨尔瓦 (92至37 mmHg) 的LVOT梯度 (p<0.001).
- 70%的患者至少有一次NYHA类改善,坚持高 (99%).
- 观察到可容忍的安全性,有13%的患者因不良事件而停止治疗.
结论:
- 马瓦卡门在澳大利亚oHCM患者中提供了显著的临床和心声学益处.
- 该药在使用的前6个月内显示出可容忍的安全性.
- 这项研究提供了澳大利亚关于mavacamten治疗的有价值的现实数据.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
451
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
451
Cardiomyopathy II: Dilated Cardiomyopathy
509
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
509
Cardiomyopathy IV: Restrictive Cardiomyopathy
496
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
496
Cardiomyopathy V: Interprofessional Care
370
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
370
Cardiomyopathy I: Introduction and Classification
545
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
545
Cardiomyopathy VI: Nursing Management
332
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
332


